 |
|
 |
- December 1, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"STOP NIDDM Trial"Prof. Avraham Karasik (biography)
English - 2005-04-15 - 19 minutes
|
 | (22 slides) |
Summary :
The STOP NIDDM trial was a multicenter, international, placebo-controlled, randomized clinical trial to assess the effect of acarbose in preventing or delaying conversion of impaired glucose tolerance (IGT) to type 2 diabetes. Patients were recruited through screening of high risk population and those with both IGT and IFG (FBG > 5.6 mmol/L) were included in the study. 714 patients were allocated to acarbose (up to 100 mg) three times daily and 715 to placebo. The primary endpoint was development of diabetes on the basis of a yearly oral glucose tolerance test (OGTT). 61 (4%) patients were excluded because they did not have IGT or had no post randomization data. 211 (31%) of 682 patients in the acarbose group and 130 (19%) of 686 on placebo discontinued treatment early . The main reason for discontinuation in the acarbose treated patients were flatulence and diarrhea. After an average of 3.3 years, 221 (32%) subjects in the acarbose group and 285 (42 %) in the placebo group developed diabetes. Using the Cox proportional hazard model acarbose reduced the risk of diabetes by 25% (relative hazard 0.75; P=0.0015). The absolute risk reduction over 3.3 years was 9.1% suggesting a number needed to treat of 11 to avoid one case of diabetes. Importantly, new diagnostic criteria were introduced after the start of the study that required confirmation of diagnosis on a separate day. Using these criteria (two consecutive OGTT, a 2 -hours plasma glucose >11.1 mmol/L), the risk reduction was 36% (relative hazard 0.64; p=0.002). In addition to delaying the progression to diabetes, acarbose was also associated with an increased reversion of impaired glucose tolerance to normal glucose tolerance (p<0.0001). At the end of the study, treatment with placebo for 3 months was associated with an increase in conversion of impaired glucose tolerance to diabetes. The results from the STOP NIDDM trial support the suggestion that post prandial hyperglycemia plays an important role in progression of glucose intolerance to diabetes. Acarbose can be used effectively to halt or delay the development of NIDDM in these high risk individuals.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- The effect of acarbose in preventing or delaying conversion of impaired glucose tolerance (IGT) to type 2 diabetes.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
